McKesson Corporation (MCK): Price and Financial Metrics
McKesson Corporation (MCK)
Today's Latest Price: $180.17 USD
Updated Jan 27 2:12pm
Add MCK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 77 in Medical - Services
See all "A" rated Strong Buy stocks
MCK Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for MCK is 39.76 -- better than 99.23% of US stocks.
- With a price/sales ratio of 0.13, Mckesson Corp has a higher such ratio than only 2.22% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, Mckesson Corp is reporting a growth rate of -1,037.21%; that's higher than merely 1.89% of US stocks.
- Stocks that are quantitatively similar to MCK, based on their financial statements, market capitalization, and price volatility, are JWN, BURL, RAD, CDW, and KR.
- MCK's SEC filings can be seen here. And to visit Mckesson Corp's official web site, go to www.mckesson.com.
MCK Stock Price Chart Interactive Chart >
MCK Price/Volume Stats
| Current price | $180.17 | 52-week high | $187.67 |
| Prev. close | $184.42 | 52-week low | $112.60 |
| Day low | $180.00 | Volume | 581,089 |
| Day high | $184.10 | Avg. volume | 975,173 |
| 50-day MA | $177.97 | Dividend yield | 0.91% |
| 200-day MA | $157.59 | Market Cap | 28.93B |
McKesson Corporation (MCK) Company Bio
Mckesson Corporation partners with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. The company was founded in 1833 and is based in San Francisco, California.
MCK Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $180.17 | $299.45 | 62% |
Below please find a table outlining a discounted cash flow forecast for MCK, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Mckesson Corp ranked in the 63th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 63.17% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Mckesson Corp, consider:
- The company has produced more trailing twelve month cash flow than 89.63% of its sector Healthcare.
- Mckesson Corp's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 11.24% of tickers in our DCF set.
- MCK's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than merely 11.24% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 59% |
| 1% | 61% |
| 2% | 62% |
| 3% | 64% |
| 4% | 66% |
| 5% | 67% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MCK, try ANTM, DGX, CAH, ANIP, and DVA.
Loading social stream, please wait...